Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
China is now focusing on establishing volume and enhancing capabilities for innovative high value drug production
The focus of the companies in this partnership is to synergise capabilities, leverage research and bring innovative products in specific therapeutic areas
Gland Pharma enters into a Put Option Agreement to acquire 100% of Cenexi Group
Steve joins Sai Life Sciences from GlaxoSmithKline (GSK) where he was a department head and member of the global chemical development leadership team.
The Group will continue to make proactive investments of its management resources in the life science business
API platform to comprise of RA Chem Pharma, ZCL Chemicals and Avra Laboratories
Through the collaboration, Lonza will gain access to Singzyme’s enzymatic conjugation platform enabling the site-specific binding of payloads with peptidic linkers to proteins of interest
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
Subscribe To Our Newsletter & Stay Updated
